



TORII PHARMACEUTICAL CO., LTD.

SHIONOGI Group Company

Tokyo, February 20, 2026

FOR IMMEDIATE RELEASE

**Announcement of Decision on Basic Policy Regarding Absorption-Type Merger
of Torii by Shionogi & Co., Ltd.**

Shionogi & Co., Ltd. ("Shionogi"), the wholly owning parent company of Torii Pharmaceutical Co., Ltd. ("Torii"), issued a press release today to the effect that, at a meeting of its Board of Directors held today, Shionogi resolved to adopt the basic policy (the "Basic Policy") to implement an absorption-type merger with the effective date scheduled for April 1, 2027. Under this merger, Shionogi will be the surviving company and Torii will be the absorbed company. Torii hereby announces that, at a meeting of its Board of Directors held today, Torii also resolved to support the Basic Policy.

Since Torii became a wholly owned subsidiary of Shionogi as of September 1, 2025, both companies have been working to build a stronger system for delivering our respective core products to a broader patient population by leveraging each company's distinct strengths and by expanding and reinforcing our medical information and promotion activities.

Torii believes that the realization of the absorption-type merger will further accelerate these initiatives and enable us to make even greater contributions to healthcare.

Please see the announcement from Shionogi at the following link:

Shionogi's Press Release (External Link)

["Notice Regarding the Determination of the Basic Policy for the Absorption-Type Merger of TORII PHARMACEUTICAL Co., Ltd."](#)

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814
E-mail: webmaster@torii.co.jp